Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 561-569

  Ranogajec, Irena ^d   Jakić Razumović, Jasminka ^a   Puzović, Velibor ^b   Gabrilovac, Jelka ^c  

^a KBC Zagreb   (Croatia)

^b Dubrovnik Regional Hospital   (Croatia)

^c Division of Molecular Medicine   (Croatia)

^d SUNCE Polyclinic ^*  (Croatia)

Author keywords

APN CD13 expression; Breast cancer; MMP 2; MMP 9; Prognosis

Indexed keywords

GELATINASE A; GELATINASE B; MICROSOMAL AMINOPEPTIDASE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER PROGNOSIS; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK FACTOR; STROMA CELL; TUMOR CELL; TUMOR VOLUME; BREAST TUMOR; CANCER GRADING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD13; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STROMAL CELLS; SURVIVAL RATE;

EID: 84864794368     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9984-y     Document Type: Article

References (43)

1. Strnad M, Hrabak-Žerjavić V, Šamija M. Epidemiology, prevention and early detection of breast cancer. In: Šamija M, Juzbašić S, Šeparović V, Vrdoljak VD, editors. Breast tumors. 1st ed. Zagreb: Medicinska Naklada; 2007. p. 27-32.
2. Lester SC, Cotran RS. The breast. In: Cotran RS, Kumar V, Robbins SLG, editors. Pathologic basis of disease. 6th ed. Philadelphia: WB Sounders; 1999. p. 1093-119.
3. Rosen PP. Invasive duct carcinoma, assessment of prognosis, morphologic prognostic markers and tumor growth rate. In: Rosen PP, editor. Rosen's breast pathology. 2nd ed. Philadelphia: Lippincott Williams/Wilkins; 2001. p. 325-56.
4. Woessner JF, Nagase H. Matrix metalloproteinases and TIMPs (protein profile). 2nd ed. In: Woessner JF, Nagase H, editors. New York: Oxford University Press; 2000.
5. Duffy MJ, Maguire TM, Hill A, McDermott E, Ohiggins N. Metalloproteinases: role in breast cancerogenesis, invasion and metastasis. Br Cancer Res. 2000;4:252-7.
6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res. 2003;2:827-39.
7. Ross JS, Linette GP, Stec J, Clark E, Ayers M, et al. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn. 2004;2:169-88.
8. John A, Tuszynski G. The role of matrix metalloproteinases in tumour angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7:14-23.
9. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer. 2008;8:74-80.
10. Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007;7:140-6.
11. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P. Expression of the extracellular matrix metalloproteinase inducer (EMMPERIN) and the matrix metalloproteinase- 2 in bronchopulmonary and breast lesions. J Histochem Cytochem. 1999;47:1575-80.
12. van Hensbergen Y, Broxterman HJ, Rana S, van Diest PJ, Duyndam MCA, et al. Reduced growth, increased vascular area and reduced response to Cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin Cancer Res. 2004;10(3):1180-91.
13. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97(3):652-9.
14. Yang E, Shim JS, Woo HJ, Kim KW, Kwon HJ. Aminopeptidase N/CD13 induces angiogenesis through interaction with a proangiogenic protein, galectin-3. Biochem Biophys Res Commun. 2007;363:336-41.
15. Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Br Cancer Res. 2002;72:69-77.
16. Tetu B, Trudel D, Wang CS. Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer. 2006; 93(9):944-8.
17. Szabo KA, Singh G. Modulation of monocyte matrix metalloproteinase- 2 by breast adenocarcinoma cells. Br Cancer Res. 2005;7:661-8.
18. Sellers A, Reynolds JJ, Meikle MC. Neutral metallo-proteinases of rabbit bone. Separation in in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans. Biochem J. 1978;171:493-6.
19. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase- 2 (MMP-2) and MMP-9 in breast cancer with a special reference to activator protein-2, Her2, and prognosis. Clin Cancer Res. 2004;10:7621-8.
20. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res. 2004;3:1057-63.
21. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem. 1990;265:11077-82.
22. Peihong S, Perry F. Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhen-Zhou Center Hospital, China. Ethio Med J. 2007;45:79-83.
23. Ogura S, Ohdaira T, Hozumi Y, Omoto Y, Nagai H. Metastasisrelated factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol. 2007;96:46-53.
24. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Br Cancer Res Treat. 1999;58:287-93.
25. Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC. Expression and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in breast carcinoma. Ai Zheng. 2003;22(9):968-73.
26. Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 2009;46(3):194-202.
27. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006;10(2):499-510.
28. Cao D, Polyak K, Halushka M, Nassar H, Kouprina N, et al. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4, overexpression of matrix metalloproteinase 9. Br Caner Res. 2008;10:R91.
29. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta. 2006;371:92-6.
30. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;6:1270-5.
31. Li HC, Cao DC, Liu Y, Hou YF, Wu J, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Br Cancer Res Treat. 2004;88:75-85.
32. Saiki I, Yoneda J, Azuma I, Fujii H, Abe F, Nakajima M, Tsuruo T. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 2006;54(1): 137-43.
33. Martinez JM, Prieto I, Ramirez MJ, Cueva C, Alba F, Ramirez M. Amino peptidase activities in breast cancer tissue. Clin Chem. 1999;45(10):1797-802.
34. Liang X, Zhao J, Hajivandi M, Wu R, Tao J, Amshey JW, Pope RM. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. Proteome Res. 2006;5(10):2632-41.
35. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL, Gatter KC. Expression of aminopeptidase-N (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol. 1994;47(1):43-7.
36. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate. 1997;33(4):225-32.
37. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M. Clinical significance of Aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 2003;9:1503-8.
38. Tokuhara T, Hattori N, Ishida H, et al. Aminopeptidase N in nonsmall cell lung cancer. Clin Cancer Res. 2006;12:3971-8.
39. Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C. Biological significance of Aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 2003;63:8500-6.
40. Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology. 2002;122(2): 376-86.
41. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60(3):722-7.
42. Garde SV, Forte AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13- expressing cells and its antitumor effects. Anticancer Drugs. 2007;18:1189-200.
43. Wickstrom M, Viktorsson K, Lundholm L, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281-90.